Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Four-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B, Part C, and Part D), Multi-Dose, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus

NCT06280703 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06280703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06280703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Four-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B, Part C, and Part D), Multi-Dose, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
May 15, 2024
Completion date
October 3, 2026
Enrollment
121 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, type 1 diabetes mellitus